Nolvadex 10 - Beligas Pharmaceuticals

Tamoxifen citrate, a non-steroidal anti-estrogen, belongs to the triphenylethylene class of SERMs. It was developed in 1962 by ICI and gained FDA approval in 1977 for treating hormone-responsive breast cancer. The compound blocks estrogen receptors in breast tissue, making it a staple in cancer therapy. Additionally, tamoxifen is utilized off-label by bodybuilders to counteract estrogenic side effects from anabolic steroids. It also stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), aiding in testosterone recovery during post-cycle therapy.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Nolvadex 10 by Beligas Pharmaceuticals, consult with your doctor or healthcare professional.